Overview

A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

Status:
Withdrawn

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide safety and efficacy data for TMC207 and to demonstrate that TMC207 added to a background regimen (BR) is superior to treatment with the BR plus placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Infectious Diseases BVBA

Treatments:

Bedaquiline
Diarylquinolines